Department Hematology, Hull University Teaching Hospitals NHS TrustHull, England, United Kingdom
n/A
(1552027) Does the Life Expectancy of Elderly CLL patients receiving upfront Targeted Agents approach the Life Expectancy of the General Population?
Saturday, October 7, 20233:50 PM – 4:00 PM EDT
(1554106) Stopping ibrutinib after 6 years of continuous exposure results in decreased or stable CLL levels for at least a year in most patients, providing further support for the STATIC trial evaluating intermittent BTKi treatment.
Sunday, October 8, 20239:45 AM – 9:55 AM EDT
